This inventor holds 5 USPTO granted patents and 3 published patent applications and 1 EPO patent. Top assignee: Cadila Healthcare Limited. Active years: 2014-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Ahmedabad, IN (2014)
- Gujarat, IN (2017 - 2019)
Company Filing History:
Years Active: 2014-2026
Title: Innovations of Kaushik M Banerjee in Diabetes Treatment
Introduction
Kaushik M Banerjee is a notable inventor based in Ahmedabad, India. He has made significant contributions to the field of diabetes treatment through his innovative patents. With a total of four patents to his name, Banerjee's work focuses on synergistic compositions that enhance the efficacy of diabetes medications.
Latest Patents
Banerjee's latest patents describe a synergistic composition that includes one or more statins, dipeptidyl peptidase IV (DPP IV) inhibitors, or biguanide antihyperglycaemic agents combined with a PPAR agonist. This composition is specifically designed for the treatment of non-insulin dependent diabetes (NIDDM) or Type 2 diabetes, along with conditions associated with diabetes mellitus. The patents also detail the preparation of these compositions and introduce novel salts of the PPAR agonist, along with processes for their preparation and use.
Career Highlights
Kaushik M Banerjee is currently associated with Cadila Healthcare Limited, a prominent player in the pharmaceutical industry. His work at the company has been instrumental in advancing diabetes treatment options.
Collaborations
Banerjee collaborates with notable colleagues such as Mukul R Jain and Suresh Giri, contributing to a dynamic research environment focused on innovative healthcare solutions.
Conclusion
Kaushik M Banerjee's contributions to diabetes treatment through his innovative patents reflect his commitment to improving patient outcomes. His work continues to influence the pharmaceutical landscape, particularly in the management of diabetes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile